Pitavastatin Is a Novel Mcl-1 Inhibitor That Overcomes Paclitaxel Resistance in Triple-Negative Breast Cancer

Researchers analyzed the impact of pitavastatin on TNBC cells was assessed in vitro by examining cell viability, apoptosis, mitochondrial function, and effects on cancer stem cell properties.